Recent Updates
Recently added Catalysts
FULC Positive Sentiment

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Thursday, March 9, 2023, at 8:00 a.m. ET

Monday, March 6, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, is set to release its fourth quarter and full year 2022 financial results on March 9, 2023. A conference call and webcast will follow at 8:00 a.m. ET to discuss these results and update on recent corporate developments. The event highlights the company's ongoing commitment to transparency and engagement with investors.
Price reaction · baseline $5.99 (2023-03-03 close) · 1 other FULC headline(s) in the window, move may be shared
day 0 close · peak
-0.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Fulcrum Therapeutics is actively communicating its financial results, indicating transparency.
  • The company is focused on rare diseases, showing a commitment to improving patient lives.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+32%
120-day peak, hindsight
Typical move
15.6%
average across 6 past catalysts
Cash runway
~59 mo
Minimal dilution risk
Lead asset
Pociredir
Phase 2 · Sickle Cell Disease

Full Press Release Details

CAMBRIDGE, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its fourth quarter and full year 2022 financial results will be released on Thursday, March 9, 2023 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.
Individuals may participate in the live call via telephone by dialing (877) 407-0792 (domestic) or (201) 689-8263 (international) and using the conference ID: 13735955 or by clicking on this link and requesting a return call. An audio webcast will be accessible through the Investor Relations section of the company’s website at www.fulcrumtx.com or by clicking here. Following the live webcast, an archived replay will also be available.
About Fulcrum Therapeutics
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
Executive Director, Corporate Communications
Fulcrum Therapeutics, Inc.

Frequently Asked Questions

When will Fulcrum Therapeutics announce financial results?

Fulcrum Therapeutics will release its financial results on March 9, 2023.

What time is the conference call on March 9, 2023?

The conference call is scheduled for 8:00 a.m. ET.

How can I participate in the Fulcrum call?

You can join by phone or through the company's website.

Where can I find the audio webcast?

The audio webcast is available on Fulcrum's Investor Relations webpage.

Will there be a replay of the conference call?

Yes, an archived replay will be available after the live broadcast.

ShareAdd on Google
Tags: FULC Viatris Investor Conferences Healthcare Fulcrum Therapeutics financial results conference call rare diseases
Last updated: Mar 6, 2023

Biotech snapshot

Cash runway
$319M liquidity · $5M/mo burn
~59 mo
Minimal dilution risk
Lead asset
PociredirPhase 2
Sickle Cell Disease →

Catalyst track record

+32%
best trade around FULC's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for FULC.

See every catalyst's timing & PoA →